 YARDLEY, Pa., Aug. 25, 2021 GLOBE NEWSWIRE -- OptiNose, Inc. NASDAQ:OPTN, a pharmaceutical company focused on patients treated by ear, nose and throat ENT and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635c4. 